Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 320 participants.

Also called NCT07396337

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 320 participants (planned count) (from the registry)
Sponsor
Changzhou Qianhong Bio-pharma Co., Ltd. (from the registry)
Registry
  • NCT NCT07396337
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07396337. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-19 (actual); primary completion 2026-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.
Condition
Acute Ischemic Stroke
Intervention (Drug)
QHRD106 Injection (Low-dose group)
Intervention (Drug)
QHRD106 Injection (Middle-dose group)
Intervention (Drug)
QHRD106 Injection (High-dose group)
Intervention (Drug)
Placebo
Lead sponsor
Changzhou Qianhong Bio-pharma Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07396337
Content hash
b7f1f62e7193d386f4cbc39e671e1846ec4f658908e7243d62a2c3a07de6c358